These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16227427)

  • 41. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP; Laurindo I; Scheinberg MA
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract]   [Full Text] [Related]  

  • 42. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J; Rudwaleit M
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
    Richette P; Viguier M; Bachelez H; Bardin T
    J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
    [No Abstract]   [Full Text] [Related]  

  • 44. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
    Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
    [No Abstract]   [Full Text] [Related]  

  • 45. Two cases of serious food-borne infection in patients treated with anti-TNF-alpha. Are we doing enough to reduce the risk?
    Makkuni D; Kent R; Watts R; Clunie G
    Rheumatology (Oxford); 2006 Feb; 45(2):237-8. PubMed ID: 16377730
    [No Abstract]   [Full Text] [Related]  

  • 46. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis.
    Lassoued S; Zabraniecki L; Marin F; Billey T
    Semin Arthritis Rheum; 2007 Feb; 36(4):262-3. PubMed ID: 17067660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute psychosis in three patients receiving anti-tumour necrosis factor-alpha therapy.
    McGregor L; Saunders SA; Hunter JA; Murphy E
    Rheumatology (Oxford); 2008 Aug; 47(8):1254-5. PubMed ID: 18515865
    [No Abstract]   [Full Text] [Related]  

  • 48. Reversible male infertility under treatment with an anti-TNFα agent: a case report.
    Wildi LM; Haraoui B
    Ann Rheum Dis; 2012 Mar; 71(3):473-4. PubMed ID: 22138196
    [No Abstract]   [Full Text] [Related]  

  • 49. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis.
    Ozorio G; McGarity B; Bak H; Jordan AS; Lau H; Marshall C
    Med J Aust; 2007 Nov; 187(9):524-6. PubMed ID: 17979620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leucocytoclastic vasculitis associated with golimumab.
    Pàmies A; Castro S; Poveda MJ; Fontova R
    Rheumatology (Oxford); 2013 Oct; 52(10):1921-3. PubMed ID: 23530254
    [No Abstract]   [Full Text] [Related]  

  • 51. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
    Roos JC; Chilvers ER; Ostor AJ
    J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
    [No Abstract]   [Full Text] [Related]  

  • 52. Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
    Dubey SG; Leeder J; Gaffney K
    Rheumatology (Oxford); 2008 Jul; 47(7):1100-1. PubMed ID: 18495822
    [No Abstract]   [Full Text] [Related]  

  • 53. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
    Algül A; Basoglu C; Kiralp MZ; Ozçakar L
    Acta Reumatol Port; 2008; 33(4):477-8. PubMed ID: 19107094
    [No Abstract]   [Full Text] [Related]  

  • 55. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infliximab-induced SLE-like syndrome involving the lung and pleura.
    Diri E; Tello W; Ratnoff WD; Nugent K
    Lupus; 2007; 16(9):764-6. PubMed ID: 17728373
    [No Abstract]   [Full Text] [Related]  

  • 57. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab.
    Fabre C; Dereure O
    Dermatology; 2008; 216(2):185-6. PubMed ID: 18216487
    [No Abstract]   [Full Text] [Related]  

  • 58. Tumor necrosis factor-alpha blocker induced tuberculosis.
    Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
    J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
    [No Abstract]   [Full Text] [Related]  

  • 59. Infection and anti-tumor necrosis factor-alpha therapy.
    Zandman-Goddard G
    Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
    [No Abstract]   [Full Text] [Related]  

  • 60. Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.
    Sangle SR; Hughes GR; D'Cruz DP
    Ann Rheum Dis; 2007 Apr; 66(4):564-5. PubMed ID: 17360788
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.